Company news

Cellectis S.A. news in 2026

Cellectis S.A.'s news releases, calls and decks from 2026, newest first.

View company

Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with.HEAL-101 at ESGCT 2026

October 27, 2026

Monthly information on share capital and company voting rights

October 6, 2026

Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company

September 14, 2026

Cellectis annonce sa transformation stratégique en société d'édition du génome in vivo

September 13, 2026

Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update

September 10, 2026

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

September 2, 2026

Cellectis Announces Participation in Upcoming Investor Conferences

September 1, 2026

Cellectis annonce sa participation à plusieurs conférences investisseurs

August 31, 2026

Cellectis Reports Financial Results for the Second Quarter 2026

August 5, 2026

Cellectis to Report Second Quarter Financial Results on August 6, 2026

July 30, 2026

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

June 25, 2026

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

June 11, 2026

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

June 9, 2026

Report of the Board of Directors - Combined General Meeting of Shareholders - June 25, 2026

May 29, 2026

Notice of Meeting - Combined General Meeting of Shareholders - June 25, 2026

May 20, 2026

Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress

May 12, 2026

Cellectis Reports Financial Results for the First Quarter 2026

May 11, 2026

Cellectis to Report First Quarter Financial Results on May 11, 2026

May 4, 2026

Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting

April 27, 2026

Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform

April 13, 2026

Monthly information on share capital and company voting rights

April 7, 2026

Annual Report for Fiscal Year Ending December 31, 2025 (Form 20-F)

March 20, 2026

Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update

March 19, 2026

Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

March 12, 2026

Cellectis Announces 2026 Strategy and Catalysts

January 8, 2026

Calls in 2026

Decks in 2026